Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER vs AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dextrose is a monosaccharide that provides a source of calories and hydration. Sodium chloride and potassium chloride replace extracellular fluid and electrolytes.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibition of protein synthesis.
Fluid and electrolyte replenishment,Correction of hypokalemia,Maintenance of hydration and electrolyte balance,Intravenous infusion for parenteral nutrition (off-label)
Treatment of serious gram-negative bacterial infections,Septicemia,Lower respiratory tract infections,Intra-abdominal infections,Complicated urinary tract infections,Skin and soft tissue infections,Bone and joint infections,Burn infections,Perioperative prophylaxis in high-risk patients
Intravenous infusion; rate and volume determined by patient's fluid, electrolyte, and caloric requirements; typical adult dose is 1000-2000 m L per 24 hours, infused at a rate of 50-100 m L/hour.
15 mg/kg/day IV divided every 8-12 hours (usual adult dose: 15 mg/kg/day).
Not applicable as a primary pharmacokinetic parameter for this combination; dextrose follows glucose disposition with a half-life of approximately 1-2 hours in euglycemic individuals, prolonged in diabetes. Electrolytes distribute and are eliminated with functional half-lives reflecting renal handling (e.g., potassium half-life ~6-8 hours).
Terminal elimination half-life: 2–3 hours in patients with normal renal function; may be prolonged to 30–60 hours in anuria.
Dextrose is metabolized to carbon dioxide and water via glycolysis and the Krebs cycle. Electrolytes are excreted or retained based on renal function.
Primarily excreted unchanged by glomerular filtration. Minimal hepatic metabolism.
Dextrose is metabolized to carbon dioxide and water, with negligible renal elimination of unchanged glucose unless hyperglycemia exceeds renal threshold. Sodium and chloride are primarily excreted renally, with >90% of filtered sodium reabsorbed; potassium is predominantly excreted renally (90%) with minor fecal loss (<10%) under normal renal function.
Renal excretion of unchanged drug via glomerular filtration; >90% eliminated unchanged in urine within 24 hours. Biliary/fecal excretion <1%.
Dextrose: negligible (<1%); sodium: negligible; chloride: negligible; potassium: negligible (<1% bound to albumin).
Low protein binding; 0–11% bound, primarily to albumin.
Dextrose: approximately 0.2-0.3 L/kg (mainly extracellular fluid); sodium: 0.25 L/kg (extracellular); chloride: 0.25 L/kg; potassium: approximately 0.5 L/kg (distributes into intracellular compartment).
Vd: 0.25–0.4 L/kg; approximates extracellular fluid volume. Increased in edema, ascites; decreased in dehydration.
Intravenous: 100% (complete bioavailability); not administered via other routes.
Intravenous: 100% bioavailable. Not administered orally (negligible absorption).
In patients with severe renal impairment (e GFR <30 m L/min/1.73 m²), reduce volume and monitor potassium closely; may require potassium restriction; dosing based on fluid and electrolyte status.
For GFR 30-59 m L/min: extend interval to every 12-24 hours; GFR 15-29 m L/min: every 24-48 hours; GFR <15 m L/min (not on dialysis): every 48-96 hours or consider dosing based on serum levels.
No specific adjustment for Child-Pugh class A or B; in severe hepatic impairment (Child-Pugh class C), monitor potassium and glucose levels; adjust rate to avoid fluid overload.
No specific Child-Pugh based modifications; monitor renal function and drug levels.
Dose based on weight: 100-200 m L/kg per 24 hours for maintenance; adjust for dehydration or electrolyte deficits; typical infusion rate 5-10 m L/kg/hour; maximum rate 15 m L/kg/hour.
Neonates: 15-20 mg/kg/day IV divided every 12 hours; Infants and Children: 15-22.5 mg/kg/day IV divided every 8-12 hours.
Use with caution due to increased risk of fluid and electrolyte imbalances; start at lower end of dosing range; monitor renal function and cardiac status; avoid rapid infusion.
Adjust dose based on renal function; monitor serum creatinine and trough levels; usual starting dose: 15 mg/kg/day with extended intervals per renal function.
No FDA black box warning.
Aminoglycosides can cause nephrotoxicity and ototoxicity. Neurotoxicity (including vestibular and auditory) may occur even at normal doses. Risk is greater in patients with renal impairment, pre-existing hearing loss, or prolonged use. Monitor renal function and eighth cranial nerve function.
Use with caution in patients with renal impairment, heart failure, or edema,Monitor serum electrolytes, glucose, and fluid status,Risk of hyperglycemia, hyperkalemia, or fluid overload,Avoid in patients with intracranial hemorrhage or hemolytic anemia
Monitor renal function and audiometric tests,Adjust dose based on renal function,Risk of neuromuscular blockade, especially in patients with neuromuscular disorders,Avoid concurrent use of other nephrotoxic or ototoxic drugs,Use caution in neonates, elderly, and patients with dehydration
Hyperkalemia,Hyperglycemia with severe dehydration,Anuria or severe renal failure,Acute intracranial hemorrhage (dextrose-containing solutions),Hypersensitivity to any component
Hypersensitivity to amikacin or other aminoglycosides,Myasthenia gravis (relative due to risk of neuromuscular blockade)
No known food interactions. However, the potassium content may need to be considered in patients on potassium-restricted diets. Dextrose may affect blood glucose levels; dietary adjustments may be necessary for diabetic patients.
No clinically significant food interactions. Maintain adequate hydration. Avoid excessive alcohol consumption.
Dextrose, sodium chloride, and potassium chloride are physiological components present in normal body fluids. There is no evidence of teratogenic risk with appropriate use during pregnancy. However, electrolyte imbalances or hyperglycemia from improper administration could pose risks to the fetus. High doses of dextrose in the third trimester may cause fetal hyperinsulinemia and neonatal hypoglycemia. Overall, FDA Pregnancy Category C: risk cannot be ruled out, but use when clearly needed.
Aminoglycosides like amikacin cross the placenta. First trimester: No evidence of major malformations, but risk cannot be excluded. Second and third trimesters: Potential for fetal ototoxicity (eighth cranial nerve damage) and nephrotoxicity, especially with high doses or prolonged use. Avoid unless compelling indication.
Dextrose, sodium chloride, and potassium chloride are normal constituents of human milk and are not expected to cause adverse effects in breastfed infants. M/P ratio: Not applicable as these are endogenous substances. The use of this solution is considered compatible with breastfeeding, provided maternal electrolyte and glucose levels are maintained within normal ranges.
Minimal excretion into breast milk (M/P ratio unknown but expected low). No reports of adverse effects in nursing infants from maternal amikacin use. Caution with infant renal impairment or premature infants due to potential accumulation. Use only if necessary.
Pregnancy can alter fluid and electrolyte requirements. Increased plasma volume (up to 50%) and glomerular filtration rate may require higher infusion rates or adjustments to maintain desired electrolyte balance. However, no specific dose adjustment is routinely recommended from standard doses; clinical judgment based on maternal weight, hydration status, and laboratory values should guide therapy.
Increased renal clearance in pregnancy may lower serum levels; consider higher doses based on therapeutic drug monitoring. Adjust for renal impairment if present. Standard initial dosing: 15 mg/kg/day IV/IM divided q8-12h, with level-guided adjustments.
This multi-electrolyte solution is commonly used for maintenance and replacement of fluid, electrolytes, and calories. Do not administer simultaneously with blood products due to risk of red cell agglutination and hemolysis. Monitor serum potassium closely in renal impairment. Use with caution in patients with heart failure or edema. Incompatible with amphotericin B, diazepam, and phenytoin.
Amikacin is an aminoglycoside antibiotic with concentration-dependent bactericidal activity. Monitor peak (20-30 mcg/m L) and trough (<10 mcg/m L) serum levels to optimize efficacy and minimize toxicity. Adjust dose based on renal function (Cr Cl). Ototoxicity (vestibular and cochlear) and nephrotoxicity are dose-limiting; audiometry and renal function tests are mandatory. Extended-interval dosing (15-20 mg/kg once daily) is preferred for most indications. Avoid concurrent use with other nephrotoxic drugs (e.g., vancomycin, loop diuretics).
Do not use this solution if the container is damaged or the solution is cloudy.,Report any signs of infusion site reactions, such as pain, redness, or swelling.,Inform your healthcare provider about all medications you are taking, especially potassium supplements or potassium-sparing diuretics.,This solution contains dextrose (sugar); monitor blood glucose if you have diabetes.,Tell your doctor if you have kidney problems, heart disease, or are on a sodium-restricted diet.
Take exactly as prescribed; do not skip doses or stop early.,Drink plenty of fluids to stay hydrated.,Report hearing changes (ringing in ears, dizziness) immediately.,Report decreased urine output or swelling in legs.,Avoid taking other medications without consulting your doctor, especially pain relievers like ibuprofen.,This medication is given intravenously; you may feel warmth or tingling during infusion.
"Atracurium besylate, a nondepolarizing neuromuscular blocking agent, may enhance the ulcerogenic potential of oral potassium chloride by reducing gastrointestinal motility and increasing local contact time of the potassium chloride tablet with the gastric and intestinal mucosa. This prolonged exposure can heighten the risk of gastrointestinal erosion, bleeding, or perforation, particularly in patients with pre-existing lesions or receiving high-dose potassium supplementation. Clinically, this interaction necessitates close monitoring for signs of gastrointestinal injury when these agents are coadministered."
"Methscopolamine bromide, an anticholinergic agent, reduces gastrointestinal motility and delays gastric emptying, which can prolong the contact time of orally administered Potassium chloride (KCl) tablets or capsules with the gastric mucosa. This increased exposure to high concentrations of potassium in the gastrointestinal tract potentiates the local ulcerogenic effect of KCl, leading to a higher risk of esophageal, gastric, or intestinal erosions, ulcers, hemorrhage, perforation, or stricture formation. Clinically, this interaction may present with dysphagia, epigastric pain, hematemesis, melena, or signs of acute abdomen."
"Fesoterodine, an anticholinergic agent used for overactive bladder, can reduce gastric motility and prolong gastrointestinal transit time. This effect may increase the local contact time of potassium chloride tablets with the gastrointestinal mucosa, potentiating the ulcerogenic risk of potassium chloride, which can cause esophageal or intestinal ulceration, stenosis, or perforation. The interaction is clinically significant in patients with pre-existing gastrointestinal motility disorders or those taking high-dose potassium supplements."
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER vs AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, answered by our medical review team.
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER is a Electrolyte that works by Dextrose is a monosaccharide that provides a source of calories and hydration. Sodium chloride and potassium chloride replace extracellular fluid and electrolytes.. AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibition of protein synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER and AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER is: Intravenous infusion; rate and volume determined by patient's fluid, electrolyte, and caloric requirements; typical adult dose is 1000-2000 m L per 24 hours, infused at a rate of 50-100 m L/hour.. The standard adult dose of AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: 15 mg/kg/day IV divided every 8-12 hours (usual adult dose: 15 mg/kg/day).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER and AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER is classified as Category A/B. Dextrose, sodium chloride, and potassium chloride are physiological components present in normal body fluids. There is no evidence of teratogenic risk with appropriate use during p. AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Aminoglycosides like amikacin cross the placenta. First trimester: No evidence of major malformations, but risk cannot be excluded. Second and third trimesters: Potential for fetal. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.